ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The evolving role of adjuvant immune checkpoint inhibitors in urothelial carcinoma.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCoding changes in disease definitions have influenced trends in bladder cancer epidemiologic outcomes in registries. The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable (available from the SEER Program upon request) for long-term trend analysis. This study analyzes trends in bladder cancer incidence using the harmonized staging variable.
methodsUsing SEER 12 registry data, we compared trends in the incidence of bladder cancer cases diagnosed from 1992 to 2019 using the revised (or harmonized) staging variable against the original staging variables (SEER modified AJCC third edition for 1992-2003, Derived AJCC sixth edition for 2004-2015, Derived SEER Combined for 2016-2017, and Derived EOD 2018 for 2018-2019). We used joinpoint regression to analyze changes in trends.
resultsThe data availability has improved with the revised staging system as the proportion of cases with missing lymph node and metastasis stages was substantially reduced. However, the trends varied by tumor stages between the two systems. There were generally more discontinuities in trends with the original system than with the revised system. Unlike the trend observed with the original staging system, the harmonized staging system has shown a 4% annual decrease in Tis incidence since 1992.
conclusionsWith the revised variable, we observed a consistent decrease in the incidence of Tis cases, and the trends seem smoother. IMPACT: Our study highlights the benefits of using revised staging variables to reveal previously hidden patterns, supporting the use of new variables for a more nuanced understanding of temporal trends in epidemiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.